Takeda's vedolizumab meets Phase III endpoints in UC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said vedolizumab met the co-primary endpoints in the Phase III GEMINI I trial to treat moderate to severe ulcerative colitis. The humanized mAb against integrin alpha(4)beta(7) led to a greater proportion of patients with a clinical response at week six and a greater proportion of patients in clinical remission at week 52 vs. placebo. The trial enrolled 895 patients with moderately to severely active UC who have failed at least one conventional therapy, including TNF alpha antagonists. ...